Effectiveness and safety of systemic cyclosporine for high-risk keratoplasty Masahiro Omoto 1 , Shigeto Shimmura 1 , Murat Dogru 1 , Jun Shimazaki 1 , Kazuo Tsubota 1 1Dept of Ophthalmol,Tokyo Dental Coll pp.773-776
Published Date 2004/5/15
DOI https://doi.org/10.11477/mf.1410100571
  • Abstract
  • Look Inside

We reviewed 51 high-risk eyes of 50 patients receiving penetrating keratoplasty. They were given systemic cyclosporine A to prevent immune graft rejection. High risk was defined as the presence of corneal neovascularization in 2 or more quadrants or repeat keratoplasty. During follow-up for an average of 14.9±10.2months,the graft remained transparent in 37 eyes(73%). Allograft rejection developed in 13 eyes(26%). As temporary side effects,hiccups,abdominal pain,systemic hypertension,mental confusion,and dysuria developed in one patient each. The findings show that systemic cyclosporine A is safe and effective in preventing immune graft rejection if protocol is strictly adhered to.

Copyright © 2004, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院